A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

NCT05232825 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

236

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerosis
Primary Progressive Multiple Sclerosis

Interventions

DRUG: Ocrelizumab IV
DRUG: Ocrelizumab SC
DRUG: Methylprednisolone IV
DRUG: Diphenhydramine IV
DRUG: Dexamethasone given orally
DRUG: Desloratadine given orally

Sponsor

Hoffmann-La Roche